Results 101 to 110 of about 1,814 (132)

Posterior reversible encephalopathy syndrome across 22 VEGF-pathway inhibitors in the FDA adverse event reporting system: reporting patterns and reporting-interval characteristics. [PDF]

Front Pharmacol
Li J, Cheng Y, Yang Y.
europepmc   +1 more source

Peep into anti-vascular endothelial growth factor. [PDF]

Indian J Ophthalmol
Verma L, Singh S, Ramachandran O.
europepmc   +1 more source

Brolucizumab versus aflibercept in treating exudative age-related macular degeneration: a 12-month pro re nata regimen. [PDF]

Sci Rep
Kikushima W, Sakurada Y, Fukuda Y, Yoneyama S, Kotoda Y, Tsuru DV, Kashiwagi K.   +6 more
europepmc   +1 more source

Evaluating the efficacy and safety of brolucizumab versus aflibercept on visual and anatomical outcomes in diabetic macular edema: a retrospective comparative study. [PDF]

Graefes Arch Clin Exp Ophthalmol
Saad EME, Abdelmaged WKA, Alyan A, Dabour SA, Tabl AA.   +4 more
europepmc   +1 more source

Cost-effectiveness analysis of Brolucizumab compared to Aflibercept and Ranibizumab in nAMD with persistent retinal fluid. [PDF]

Eur J Ophthalmol
García-Serrano Fuertes R, Romero Martínez A, Suarez Pérez J, López Herrero F, Cabanás Jiménez M, Flores Córdoba A, Sánchez Vicente JL.   +6 more
europepmc   +1 more source

Efficacy of anti-VEGF single-chain variable fragment AAV-based gene therapy in a laser-induced choroidal neovascularisation mouse model. [PDF]

Mol Ther Adv
Salman A, Griffiths H, Garba K, Lynn SA, Cree AJ, Szczepan M, Jashal CB, Chozhavel T M R, Rao P, Modi K, MacLaren RE, Yuen HM, Lotery AJ.   +12 more
europepmc   +1 more source

Outcomes of Re-Switching Anti-Vascular Endothelial Growth Factor after Brolucizumab-Associated Inflammation in Age-Related Macular Degeneration. [PDF]

Korean J Ophthalmol
Suh YK, Lee SH, Kim MS.
europepmc   +1 more source

U.S. trends of anti-vascular endothelial growth factor use from 2017-2023: An analysis of medicare, medicaid, and commercial insurance. [PDF]

PLoS One
Malhotra K, Colcombe J, Patil S, Vail D, Parikh R.   +4 more
europepmc   +1 more source

Anti-vascular endothelial growth factor therapy for posterior segment diseases: Progress, challenges, and the road ahead. [PDF]

Indian J Ophthalmol
Mishra C, Mohanty N, Purohit S, Orugonda U, Patil V.   +4 more
europepmc   +1 more source

Predictive value of uninterrupted dry macula duration for discontinuation of anti-VEGF therapy in diabetic macular edema. [PDF]

Sci Rep
Murata T, Hirano T, Ideta S, Tanaka K, Shimura M.   +4 more
europepmc   +1 more source